We were delighted to talk to Masanori Terashima about the advantages of robot-assisted gastrectomy for clinical stage T1-2N0-2 gastric cancer patients (Clinical Trial Identifier: UMIN000039825).
The abstract ‘Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-2N0-2 gastric cancer patients: Japan Clinical Oncology Group study JCOG1907 (MONA LISA study)’ (ABSTRACT NUMBER: TPS254) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
- Could you give us a brief overview of the postoperative complications that may occur after surgery in gastric cancer, and their prognostic significance? (0:14)
- What are the advantages and limitations of laparoscopic gastrectomy compared with open gastrectomy? (0:55)
- Could you tell us a little about robot-assisted gastrectomy and its clinical development to date? (2:02)
- What are the aims and design of the JCOG1907 study? (3:05)
- What does the future hold for robot-assisted surgical procedures in oncology? (3:52)
Disclosures: Masanori Terashima has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
Share this Video
Related Videos In Gastrointestinal Cancers
Upper gastrointestinal cancer highlights – KEYNOTE-585, KEYNOTE-811, MATTERHORN and SANO: Ken Kato, ASCO 2023
Data released from the KEYNOTE-585 (NCT03221426), KEYNOTE-811 (NCT03615326), MATTERHORN (NCT04592913) and SANO (NCT05491616) trials, were some of the most anticipated results and highlights in upper gastrointestinal cancer presented at EMSO 2023. To summarise the findings from these key studies and their impact on the treatment of upper gastrointestinal cancers we caught up with esophageal oncologist […]
Thierry André, ASCO 2023: The SOLISTICE phase III study, trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer
The SOLISTICE phase III study aimed to assess trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer. In this touchONCOLOGY interview, we speak with Dr Thierry André (Hôpital Saint-Antoine, Paris, France) to discuss the rationale for the use of trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer, the secondary endpoint of overall survival and the key […]
Michael K Gibson, ASCO 2023: Highlights in upper GI oncology
touchONCOLOGY spoke with editorial board member Michael K Gibson (Vanderbilt University, Nashville, TN, USA) to discuss his highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023 in the field of upper GI oncology, including the phase 3 ATTRACTION-5 study and a randomized, phase II study assessing toripalimab for the treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!